text:
West Coast Kustoms' Fifth Memorial Weekend in Santa Maria
It's been three decades since the formation of West Coast Kustoms (WCK), a family based organization formed by then newly transplanted Californians, Rich and Penny Pichette. Created solely due to the couple's passion for custom cars, it was a way for a tight-knit group of friends to enjoy their hobby together at a time when the majority of organized functions in SoCal were dedicated solely to street rods. From its grassroots beginnings in the lot of the Pichette's Jet Drive-In located in Sunnymead, it's hard to say if anyone could've ever imagined what the future held in store for WCK—or more importantly, what WCK would do for the custom car scene on the West Coast … and beyond.
If you're relatively new to customs, you may not realize the full story behind WCK and its contributions to the custom car world, as many of us have now come to know it. Despite the caliber and size of their Santa Maria show, which is now in its fifth year at the city's Fairpark, it's a relatively new venue for their Cruisin' Nationals. For a quarter-century prior, the Pichettes had taken a startup assemblage, consisting of a select group of traditional custom enthusiasts and, from the edges of Lake Nacimiento and on to the grassy, tree-filled central park of Paso Robles, nurtured what was to become the largest event of its kind, ever. To all the world, it was simply known as Paso. And up until 2007, every Memorial Day weekend saw thousands of pre-'64 customs make the journey to the otherwise-quaint winery town just north of San Luis Obispo from as far as Florida, New York, and Canada (on occasion, cars were shipped over from Europe and even Japan).
The trek to Paso was commonly referred to as a "pilgrimage", and that's exactly what it was in custom car terms, as nowhere else on earth could you religiously find the sheer number of famous customs and the legends responsible for creating them in the same place at the same time. But what also contributed to the show's popularity was the uniqueness of the venue's borderless setting, something no other similar event of its size and magnitude has ever afforded. And because of that, trailering of cars was rare at best, which for many, myself included, made the drive to and from a big part of the Paso experience—not quite as big as the show itself, mind you, but important nonetheless.
After 25 years, the city of Paso Robles and the Pichettes were having a hard time seeing eye to eye, and 2008 became a huge turning point. Knowing full well of the situation, Santa Maria was open arms to WCK, bringing its show south down Highway 101. Without skipping a beat, and despite Rich battling Alzheimer's, the Pichettes made the move following Paso 2007 and the very next Memorial Weekend saw the Cruisin' Nats first showing at its new home, Santa Maria's Fairpark. Sadly, Rich's bout ended in July 2010, but Penny has persevered and with the help of her family and all the devoted WCK reps, the show goes on, still holding title as the biggest custom car gathering on the planet.
I must admit that a certain part of the Cruisin' Nats' mystique and allure that drew me in was lost when the show relocated. But that hasn't stopped me from going, not by a long shot, and when I get my '47 up and running, my yearly pilgrimage will continue—and just as it's been since 1990, the calendars will be marked accordingly every Memorial Weekend.
20 Years Of Purple Badness The Beatniks Celebrate Two Decades … In Koolsville
Car clubs are a main fixture of our hobby; they've bonded "like minds" together ever since the automobile was perceived for more than just a mode of transportation. Born out of solidarity and necessity mostly for sanctioned racing, today's clubs are anything but typical—but they're still as vital if not more than ever. One automotive fraternal organization in particular, The Beatniks, is just as much a vital component in regards to West Coast Kustoms' Cruisin' Nationals as it is to the custom hobby in general. This past year marked their 20th anniversary, and in celebration, the club held a not-so-small gathering at the appropriate Mendenhall's Museum in nearby Buellton, California.


text:
Qatari people carry genetic trace of early migrants out of Africa
Shards of ancient DNA have been preserved in genomes for 60,000 years
COLD SPRING HARBOR, N.Y. — Genetic heirlooms of the some of the first modern humans to migrate out of Africa have been passed down to modern Qataris.
Located on the Arabian Peninsula, Qatar would have been an ideal stop for humans migrating out of Africa, said Juan Rodriguez-Flores, a computational geneticist at the Weill Cornell Medical College in New York City. He and his colleagues reasoned that genetic signatures of early migrants from Africa might still be present in the DNA of modern Qataris.
The researchers examined the genomes of more than 2,300 Qataris and found short stretches of DNA that indicate a population crunch about 60,000 years ago, about the time small bands of migrants are thought to have originally left Africa. Rodriguez-Flores presented the results May 9 at the Biology of Genomes meeting.
These shards of ancient DNA may have stuck around so long because they give people who carry them an evolutionary advantage, Rodriguez-Flores said, although he does not know what the advantage might be.
J. L. Rodriguez-Flores et al. The Qatari genome: novel, rare and population specific genetic variation in the Middle East of potential relevance to human disease. Biology of Genomes meeting, Cold Spring Harbor, N.Y., May 9, 2014.

subset: commoncrawl


text:
Guangxi Cummins Engine Company Celebrates Official Start of Operations with Completion of First Engi
Guangxi Cummins Engine Company Celebrates Official Start of Operations with Completion of First Engine
LIUZHOU CITY, Guangxi Province, China--(BUSINESS WIRE)-- Today, the first Cummins L9.3 engine rolled off the production line at Guangxi Cummins Engine Company Limited (Guangxi Cummins), the 50:50 joint venture between Cummins Inc. (NYS: CMI) and LiuGong Machinery (Shenzhen: 000528), marking the official start of operations in Liuzhou, southern China.
The 9.3-liter engine is designed and built in China specifically for construction equipment to meet the demand of both LiuGong and other equipment manufacturers. The engine is available in multiple versions to meet various off-road emissions standards.
"This new engine will complement Cummins existing product and manufacturing capabilities in China and focus specifically on the mainstream domestic construction markets," said Dave Crompton, Vice President, Engine Business, Cummins Inc. "It signifies an important move for Cummins to invest in meeting the unique demands of the local market by optimizing for performance, fuel economy and cost. I am confident that this customer-focused approach is laying a solid foundation for the continuous success of the new product platform and that of the new joint venture."
Evolved from the world class Cummins L8.9 engine platform, the L9.3 engine is rated 162 kW (220 hp) and offers superior low-end torque for wheel-loader applications with 5T-bucket load. With specially designed and patented power curve for wheel loaders and optimized combustion for wheel loader duty cycles, the L9.3 engine is uniquely positioned to meet customer requirements for strong power delivery, fast response and operational efficiency. The optimized components and engine features are engineered to deliver high reliability, improved fuel efficiency and performance for off-highway customers.
"Guangxi Cummins enjoys a natural advantage in leveraging Cummins technological leadership and LiuGong's rich application experience in the construction machinery market," said Steve Chapman, Group Vice President for China and Russia, Cummins Inc. "This unique value proposition is of vital importance while we explore more market opportunities with an expanded product portfolio. As construction machinery OEMs in China play an increasingly important role in the global market, we expect that the development and optimization of Cummins engines for their equipment will add value to the industry."
Guangxi Cummins is the first Cummins manufacturing facility in China dedicated to providing power for the construction machinery market. It is also one of the largest production facilities for off-highway diesel engines in China. The total investment on the company exceeds RMB 1 billion (US $160 million). Covering an area of 200,000 square meters, the initial production capacity is expected to reach 50,000 units per year, with the ability to expand the volume higher in the future when market demands increase.
"The establishment of Guangxi Cummins further expands the decade-long strategic cooperation between Cummins and LiuGong. We are delighted to be able to complement our vigor and strength with Cummins' expertise and leading technology," said Zeng Guang'an, President of LiuGong. "The joint venture will be vital in building the unique competitive advantage of LiuGong construction machinery in the China market, as well as in our efforts to penetrate into international markets."
About LiuGong
For more than 50 years, LiuGong Machinery Corporation has been a leader in China's construction equipment manufacturing industry. From building the country's first modern wheel loader, LiuGong has evolved to become one of the fastest growing, global, full-line CE companies in the world. LiuGong delivers opportunity to its employees, quality products and services to its customers, financial success to its investors, and community support in the regions it serves.
About Cummins
Cummins Inc., a global power leader, is a corporation of complementary business units that design, manufacture, distribute and service diesel and natural gas engines and related technologies, including fuel systems, controls, air handling, filtration, emission solutions and electrical power generation systems. Headquartered in Columbus, Indiana, (USA) Cummins currently employs approximately 46,000 people worldwide and serves customers in approximately 190 countries and territories through a network of approximately 600 company-owned and independent distributor locations and approximately 6,500 dealer locations. Cummins earned $1.65 billion on sales of $17.3 billion in 2012. Press releases can be found on the Web at www.cummins.com or www.cumminsengines.com. Follow Cummins on Twitter at http://twitter.com/cumminsengines and on YouTube at http://youtube.com/cumminsengines.
About Cummins China
China has become one of Cummins fastest-growing geographical markets. In 2012, Cummins' consolidated and unconsolidated sales in China exceeded $3 billion. As the largest foreign investor in China's diesel engine sector, Cummins operates 28 facilities in China, including 17 manufacturing sites that produce engines, turbochargers, filters, emission solutions, fuel systems, alternators and electrical power generation systems. In the aftermarket support area, Cummins has 12 regional service centers, 34 Customer Support Platforms and over 2000 authorized dealers of Cummins wholly-owned and JV entities across the region.
Cummins Inc.
Jon Mills, Director - External Communications, 317-658-4540
Email: email@example.com
KEYWORDS: United States North America Indiana
The article Guangxi Cummins Engine Company Celebrates Official Start of Operations with Completion of First Engine originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


text:
- This event has passed.
Knitters & Natters
10 September, 2018 @ 3:00 pm - 5:00 pm
|Recurring Event (See all)
Weekly on the same day
Event Navigation
Do you enjoy knitting or sewing? Why not join our weekly Knitters & Natter group, every Monday 3-5pm in the Oak Room.
Meet, chat and make whilst enjoying tea and delicious homemade cakes from the King's Arms cafe.


text:
In February of 2008 myself and 10 others traveled to Costa Rica for a mission trip of building a feeding center in Sherioles, Costa Rica. I did not take Spanish in High School and not until August of 07 did I even have any interest in learning it. I took some beginning Spanish at the community college where we live (my wife and I). So we planned to continue on with our Spanish so we spent a week in Playa Del Carmen, MX at a language school. When we were returning from Mexico the environment was so different at the school back in the US. I knew that traditional classes were not going to get me ready for the mission trip coming up. That's when I ordered Rosetta Stone. I received it quickly and begin to learn. I received in December and our trip was only two months away. I used the software everyday. I was shocked that after only a week of using the Software that I had learned more than at the college that i spent an entire semester trying to memorize vocab.
I continued through the software and when it was time for the trip i was very nervous about remembering all the words and phrases that i had learned. We arrived in Costa Rica and I greeted our driver and begin conversing with him in Spanish for about 20 minutes or so. He asked me how many years i had be studying Spanish and i was able to reply to him in Spanish that i had only begun about 3 or 4 months ago. He was very impressed. I have tried classes, tapes, language school and nothing compares with Rosetta Stone. I could not believe how quickly I was able to begin speaking and communicating in another language all without memorizing vocab and phrases. Conversation was made easy because of the style Rosetta Stone uses to teach you the language! Our mission trip was great and I was able to use it on the construction site and to get us around for the week. Things that would have never got done because of language barriers got done because of Rosetta Stone. It was Awesome!!! Myself and one other gentlemen who is fluent in Spanish were the only ones that were able to translate to the others what our host was talking about. Thanks Rosetta Stone for Everything you do. Were heading to Mexico this summer for another mission trip and I feel even more comfortable with my Spanish. I own Levels 1-3 and they are great!!
Effingham, Illinois
Find more posts about: Spanish


text:
MU Extension > calendar
Professional development events
Relatives As Parents--Northland Grandfamilies (Session 4 of 5)
Tuesday, April 1, 2014, 5:30 p.m. to 7:30 p.m.
Kearney Middle School200 E. 5th Street, Kearney MO map...
The Northland Grandfamilies Program strives to raise awareness of issues facing grandparents/aunts/uncles who are raising grandchildren or nieces and nephews under the age of 18. In addition to providing support groups, programs and resources for the grandfamily participants; staff members also present informative programs and educational displays/exhibits throughout the Northland community to increase public knowledge and awareness. Venues include Parent Fairs, service club meetings, and volunteer trainings.
Session topic:
Northland Grandfamilies will be providing an educational exhibit at the Kearney-Holt CAN annual "Family University". Come and learn more about this program which serves grandparents, aunts & uncles who are raising grandchildren/nieces/nephews.
For more information on educational programs and exhibits related to the Northland Grandfamilies Program, contact the University of Missouri Extension Center at 816-407-3490
Class size:
Event full:
Add event to your compatible iCalendar such as Microsoft Outlook or Apple iCal.
© 1993
to 2015 Curators of the University
of Missouri, all rights reserved, DMCA
and other copyright information
University of Missouri Extension is an equal opportunity/ADA institution.
University of Missouri Extension
© 1993
to 2015 Curators of the University of Missouri, all rights reserved


text:
Weekend McMahon tournament, held in Scotland
Early events were called the Edinburgh tournament and subsequently developed into the two-day Scottish Open.
After several years in Edinburgh, it moved to Glasgow, before moving via Aberdeen to Dundee. There was no event in 2002 because of the British Go Congress in Edinburgh. From 2013 it returned to Glasgow and 2017 back to Edinburgh.
Registration Saturday by 09:45. Prize Giving at 18:30 Sunday


text:
I chose to come to Northwest University because I wanted to pursue their educational program. I did my undergraduate work there, and while I was pursuing my education they began the Master in Teaching program.Watch the Video
I chose to do the MIT program because I was currently a teacher, teaching in Lake Washington public schools, and it just seemed like a perfect fit. I was able to get to class after work, and it was a great opportunity for professional development.Watch the Video
I loved Northwest. I loved the opportunity to work with my cohort; it was fun to develop as fellow educators. I enjoyed the opportunity to really know my professors, and have them come and even see – observing in the classroom – and getting just great techniques.Watch the Video
First of all, it was two nights a week, which really worked with my schedule. It made it feasible and interactive. It was very fun to go to class and be with people who were all going and doing the same profession.Watch the Video
Now that I have completed the MIT program, I am a current teacher in the Lake Washington School District. I'm teaching first grade, which is my dream job, and I just give God thanks for the opportunity to use my education on a daily basis.Watch the Video
I would encourage people thinking about looking into a master's program to really consider Northwest because there is such a great opportunity to grow as a professional with the MIT program.Watch the Video


text:
YORK, Pa – The York College men's swimming team cruised to a pair of victories Friday evening in York besting both Gallaudet University and Penn State-Altoona by scores of 110-90 and 113-69, respectively. With the pair of triumphs, the Spartans improve to a solid 9-2 on the season.
Contributions came for everywhere Friday night as the Green and White secured points from numerous swimmers. The night began with the 400 medley relay, an event in which the Spartans captured first, second, and third. The Spartan crew of Cody Latchford, Steven Mercer, James Kovach, and Alex Diehl captured first with a 3:50.56.
On the individual front, a number of Spartans put together quality finishes including several triumphs.
In the quick sprint which is the 50 freestyle, Kovach claimed first-place with a time of 23.11. Two spots behind him, teammate Jamie Hicks finished his sprint in 23.80.
The Green and White continued the night's success courtesy of Latchford and Bonner, who teamed up to snag first- and second-place points in the 200 individual medley. Latchford's 2:07.50 set the pace in the event while Bonner finished less than a second later at 2:08.21.
In another 1-2-3 finish, Andy Woods led the charge in the 100 butterfly. Senior captain Richard Janosky and freshman Adam Schin followed Woods's 55.59 with times of 57.43 and 58.76, respectively.
The Spartan individual night concluded with the 100 freestyle where again York claimed first and second place. Jack Gottschalk completed his four laps in a time of 50.16 while Tyler Ziegler followed up two seconds later with a 52.16.
In the first individual men's event of the evening, York followed the impressive start by the relay teams, as Aaron Ward and Peter Zientara garnered points in the 1,000 freestyle event. Ward posted a second-place finish with a time of 12:17.20. Zientara followed up seconds later in third place with a time of 12:26.49.
In the next event, the 200 freestyle, Gottschalk and Bryant Hughes repeated the performance of Ward and Zientara finishing second and third, respectively. Gottschalk completed the event in 1:49.98, trailed by Hughes with a 1:57.11.
The Spartan men look to continue their winning ways on Saturday, December 10, as they take on Elizabethtown College at 1:00 in the York College Natatorium.
PHOTO: James Kovach swims the butterfly during York's meet against PSU-Altoona and Gallaudet Friday evening from the Grumbacher Sport & Fitness Center. Courtesy of Joe Wydner - York College (Pa.) Athletic Communications Practicum Student.
Meet recap written by Joe Wydner - York College (Pa.) Athletic Communications Practicum Student.


text: A man from the United Arab Emirates was stopped in the Bangkok airport after security officials opened his luggage and found the following: two monkeys, two panthers, two leopards, and a bear. The animals, all babies, yawned when the luggage was opened, which sounds cute but also sad, because they'd been heavily sedated. Animal trafficking is apparently common in Thailand, but smuggling mammals on this scale is rare.


text:
Discussion in 'Developers' Forum' started by redray, Mar 30, 2013.
I made a new ISPConfig Logo. Hope you like it.
The attached logo is for the ispconfig.org Homepage.
Very good and more interesting than the current one. Would you happen to have a SVG "master" of this image?
it looks good, maybe even 3 or 4 other design.
I would keep the image part and the idea of the "I" as network-pipe.
Fonts and colours could be changed ...
I invite everyone to make changes
The vector-files are to big to upload here. I put them in the svn-Folder: /docs/
red colours like the actual logo
red colours like the actual logo
blue version
blue version
blue + cold grey version
blue + cold grey version
Thanks for your work. We have already developed a new logo for ISPConfig with a german designer which we will publish soon.
Perfect. The main thin is that the old "Logo" will be replaced. I'm curious how the new logo will look like ...
cheers Martin
Separate names with a comma.


text:
» Grade 1
Grade 1
Unit A:
Plants, Animals, and People
Unit B:
Living Things and Where They Live
Unit C:
Earth, Our Home
Unit D:
Weather and the Sky
Unit E:
Describing Matter
Unit F:
Energy Sources and Motion
Houghton Mifflin Science
Education Place
Site Index
Copyright © Houghton Mifflin Company. All rights reserved.
Privacy Policy
Terms and Conditions of Use


text:
LocationSalt Lake City, UT
14295 Minuteman Dr.
Draper, UT 84020
Used 2018 Winnebago Vista 31KE
Enjoy traveling the countryside in this Winnebago Vista class A gas motor home which features a large single slide for added comfort.
Step inside model 31KE and notice the sofa bed and u-shaped dinette slide straight ahead. Both feature seat belts for safety as you ride along. The slide also creates a large area of extra floor space to move about.
To the left of the entry door there is a counter area with a location for a 32" HDTV, a double kitchen sink, and a three burner range, plus refrigerator.
Just beyond the slide you will find a convenient shower along the curb side, and a private toilet area with sink along the road side including an overhead cabinet above the toilet. There is a folding door that can separate the bathroom from the bedroom area as well.
In the rear bedroom space enjoy a comfortable queen size bed with one bedside wardrobe, and one bedside shirt closet, plus a second wardrobe just off the foot of the bed along the road side, and so much more!
Like most: It is a pleasure for me to write this letter of commendation on behalf of several of your employees in Orange Park, Florida, who have displayed exemplary and professional service to me and should be commended. These individuals are Alan Dulberger, Harry Rosenburg, and Frank Krawczyk. I have been a RV owner for more than 13 years and love it. My first RV was purchased with Dick Gore. My ... More » - Lee from Orange Park, FL
Stock# 178134
Chassis: Ford F53
|31 ft 6 in
|Ext Width
|8 ft 6 in
|Ext Height
|12 ft 2 in
|Int Height
|6 ft 8 in
|Hitch Weight
|5000 lbs
|Gross Weight
|16000 lbs
|Fresh Water Capacity
|64 gals
|Grey Water Capacity
|57 gals
|Black Water Capacity
|41 gals
|Furnace BTU
|30000 btu
|Onan 4000
|Fuel Type
|Ford F53
|Fuel Capacity
|80 gals
|190 in
|Available Beds
|Refrigerator Type
|Two Door with Freezer
|Cooktop Burners
|Shower Size
|25" x 30"
|Number of Awnings
|Axle Weight Front
|6500 lbs
|Axle Weight Rear
|11000 lbs
|LP Tank Capacity
|Water Heater Capacity
|6 gal
|14800 btu
|Basement Storage
|168 cu. ft.
|TV Info
|Awning Info
|17" Powered with LED Lights
|Gross Combined Weight
|23000 lbs
|Shower Type
The Company markets its recreational vehicles on a wholesale basis to a diversified dealer organization located throughout the U.S., and Canada.
Mission Statement at Winnebago Industries - "Moving forward with innovation and quality." Winnebago remains committed to providing its customers high quality, great value, efficient design, and eye-catching style in all the recreational vehicles it produces.
General RV works hard to ensure the accuracy of all its listings however we are not responsible for any misprints, typos, or errors found in our website pages. Any price listed excludes sales tax, registration tags, and delivery fees. Manufacturer-provided pictures, specifications and features may be used as needed. Inventory shown may be only a partial listing of the entire inventory. Please contact us at 888-436-7578 for availability as our inventory changes rapidly. All calculated payments are an estimate only and do not constitute a commitment that financing or a specific interest rate or term is available.


text:
Statement by Lawrence H. Thompson,
Principal Deputy Commissioner of Social Security,
before the House Committee on Ways and Means,
Subcommittee on Oversight
June 22, 1995
Madame Chairman and Members of the Subcommittee:
I am pleased to be here today to discuss the role of the Social Security Administration (SSA) under the Coal Industry Retiree Health Benefit Act of 1992 (Coal Act). Let me begin by briefly reviewing the requirements of the law and the responsibilities which were assigned to SSA. Then, I will discuss SSA's progress in carrying out these responsibilities.
Requirements of the Law
The Coal Act merged the 1950 and 1974 benefit plans of the United Mine Workers of America (UMWA) into a new "Combined Fund," administered by a board of trustees as a private tax-exempt employee benefit plan. This new Fund is designed to provide lifetime health benefits (and death benefits) for beneficiaries of the old plans--retired miners and their dependents or survivors. Benefits are financed from funds transferred from UMWA pension plans, premiums paid by coal operators, and transfers of amounts from the Abandoned Mine Land Reclamation fund.
Under the law, coal operators pay premiums for all beneficiaries who are determined to be their responsibility. The premiums are established by formulas in the law. The law provides for them to pay a pro rata share of the premium cost for beneficiaries for whom no assignment of responsibility can be made (unassigned beneficiaries). However, because the Fund had adequate financing for the two years ending September 30, 1995, the coal operators did not have to pay premiums for unassigned beneficiaries for those years. With the plan year beginning October 1, 1995, these premiums will be transferred to the Fund by the Department of the Interior out of the Surface Mining Control and Reclamation Trust Fund.
SSA Responsibilities
SSA was assigned three responsibilities under the Coal Act:
- To calculate the amount of the health benefit premium for each beneficiary;
- To assign each miner to a coal operator who will be responsible for the health {and death) benefit premiums for that miner and any beneficiaries eligible because of their relationship to the miner, and notify the operator of that assignment; and
- To decide requests by the coal operators for review of assignments.
Let me now briefly discuss each of these responsibilities of that employment, and the date the wage agreement was signed by the operator and the UMWA.
More specifically, the law states that a miner must be
assigned to a coal operator according to the following order
of priority:
- To the last active signatory operator (as defined previously) for whom the miner worked at least 2 years under a UMWA agreement (or if an inactive signatory, to its related company, if any) provided that the operator is also a 1978 signatory.
- To the last active signatory operator for whom the miner worked under a UMWA agreement (or if an inactive signatory, to an active related company, if any) provided the operator is also a 1978 signatory.
- To the active signatory operator of any agreement for whom the miner worked the longest under a UMWA agreement (or if an inactive signatory, to an active related company) in the period prior to 1978.
- If no assignment can be made under the above criteria, the miner is treated as "unassigned." This means that, because responsibility for the premium cannot be assigned to a particular signatory operator, the miner is assigned to a pool, for which each assigned operator pays a pro rata share of the premiums.
Before we could even begin the assignment process, we had to develop lists of assignable coal operators. These lists were developed by SSA using information which was provided to us by the Bituminous Coal Operators Association and the UMWA, SSA employer records, information provided by operators in court suits and testimony in those suits, and other available sources of information on the coal mining industry, such as the Keystone Manual. It was very difficult to develop an accurate list of coal operators because most sources of information on companies did not include the employer identification number which SSA records use to differentiate companies with similar (often identical) names. We used as much information as was available, such as similar addresses, but still had many companies erroneously included in the information provided by the UMWA. In fact, we continue to update the lists throughout the assignment process and the review process as we learn more about the companies.
In order to make an assignment using the criteria I described above, we must perform two separate operations: searching Social Security earnings records to reconstruct a miner's individual employment history; and matching that history
SSA spent $8 million of the supplemental appropriation in Fiscal Year 1993, and carried over $2 million into Fiscal Year 1994. SSA spent another $1.3 million of the supplemental in Fiscal Year 1994, and carried over $0.7 million into Fiscal Year 1995. If SSA receives requests for reviews of subsequent assignments at a rate comparable to the rate of requests for review of the initial assignments, we estimate the cost could increase by as much as $10 million. We expect this amount to be spent over the Fiscal Year 1995-1996 period. Part of this work will be funded through the remaining supplemental appropriation, and the balance from the administrative expense account, with subsequent reimbursement from general revenues.
In conclusion, Madame Chairman, despite being given a difficult and complex task, SSA has carried out all of its responsibilities under the Coal Act concerning the calculation of premiums and the initial assignment of miners to operators. We continue the process of adjusting the status of the assigned miners as companies bring out new facts about corporate relationships and are processing the remaining requests for review as quickly as we can. I would be happy to answer any questions you may have.


text:
Out of the laboratory and into the bathroom cabinet: designing and implementing clinical trials. (Clinical Trials).
Once a drug candidate has been identified and undergone study in the laboratory and animals, it enters clinical trial, usually composed of 3 phases. Generally, as the drug candidate goes from phases 1 to 3, the number of volunteers exposed to it increases and the duration of study lengthens. Each phase serves a unique purpose, and each builds on the knowledge gleaned from the earlier research.
Not all clinical trials involve an investigational drug. Some involve medical devices (for example, an insulin pump) and some examine clinical management strategies. The recently launched SMART study (Strategies for the Management of Anti-Retroviral Therapy), which pits early anti-HIV treatment against delayed anti-HIV treatment, is an example of such a study. However, this article focuses on the clinical trial of medications for treating HIV infection.
Although often given long titles and identified by imposing acronyms, a clinical trial of a drug candidate is simply a scientific way to answer specific questions about the new therapy. The questions usually differ from one phase of research to the next. For potential study volunteers, it's important to remember that the question a study asks may not be well thought out or the answer unimportant. All clinical studies are not created equal. Also, most clinical trials of anti-HIV drugs are intended only to obtain regulatory approval for marketing the drug. The trials do not necessarily tell patients and clinicians how best to use a drug. For example, abacavir sulfate (Ziagen) received regulatory approval when research showed that it lowered viral load. But many clinicians are still unsure of whether to use abacavir as part of a first treatment regimen or to save it for later, or whether to combine it with a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor.
Phase 1
In a phase 1 study, researchers usually expose only a handful of volunteers--sometimes not more than 10, and rarely more than 80--to the new therapy. The reason for this is simple: a phase 1 study marks the first time humans receive an investigational drug and researchers want to minimize harm if the therapy proves unsafe. A phase 1 study allows investigators to determine the side effects and safe dose of a new treatment. Put as a question, the phase 1 study asks: "Is this drug safe for people to take, and if so, at what dose?" Phase 1 studies almost never ask, "Is this drug effective?" It can be tempting for research participants, especially if they are eagerly awaiting a new treatment, to just assume that any new drug is effective. But the question of effectiveness--and the answer to it--comes later. Although essential to the process of clinical research, a phase 1 study carries the greatest risk to study volunteers.
Phase 2
If the results from the phase 1 study indicate that a drug is safe, it advances to phase 2. In phase 2, investigators may expose a couple of hundred people to the experimental therapy, allowing for further characterization of the drug's safety profile. Phase 2 usually marks the first time that researchers examine whether a drug is efficacious. In the context of HIV clinical therapy research, efficacy means the ability of a drug to produce a therapeutic change at the maximum dose tolerated by humans.
Specifically, investigators are usually interested in changes in the CD4 T cell count or viral load or both. Changes in these surrogate markers are usually the study endpoints, and endpoints are the measurements by which a drug's efficacy is judged. Length of survival and a decrease in disease and disability are the endpoints that truly interest most physicians and patients. But measuring those kinds of clinical endpoints may take years. (The SMART study, for example, will measure clinical endpoints and will last from 6 to 8 years.) So to speed the process along, researchers often use surrogate markers instead of clinical indices as study endpoints. A beneficial change in surrogate markers is thought to predict or stand in for a beneficial change in clinical outcome. Conversely, a negative change in surrogate markers--a decline in CD4 T cell count or a rise in viral load--is thought to predict a negative change in clinical outcome.
That's usually true, but not always. Sometimes the therapy itself may alter the predictive value of a surrogate marker. For example, Steven Deeks, MD, has shown that HIV-infected patients who remain on a protease inhibitor do better clinically than their viral loads would indicate. Still, surrogate markers are generally accurate and their use dramatically reduces the amount of time needed to study potential new anti-HIV treatments.
Phase 3
If all goes well, an investigational drug will end up in a phase 3 study where several hundred people receive it for 6 months or longer. The purpose of this phase is to determine the efficacy of an agent in a large number of people. Phase 3 studies also allow for the detection of side effects that may not have emerged in the earlier, small studies. All phase 3 studies involve a control group. The control group does not receive the investigational agent but instead gets a placebo or, more likely nowadays, a standard of care regimen. In HIV care, standard of care treatment might include a protease inhibitor and 2 nucleoside analogs. The control group serves as a benchmark against which the investigational therapy is judged.
For phase 3 studies, investigators usually recruit patients who share certain characteristics in common. For instance, investigators may seek patients who have never before taken anti-HIV drugs, or who have a CD4 count above, or a viral load below, a specific cut-off value. The study volunteers are then randomized--or assigned by chance--to either the study group or the control group. Theoretically, randomization eliminates scientific bias and ensures that the only difference between the groups is the treatment they receive. In this way, researchers can compare the effects of the new treatment against the standard of care in a study group whose characteristics are similar to those of the control group. The requirements for participation in a study are known as the inclusion/exclusion criteria. These requirements are spelled out in the study protocol, a set of written instructions for the conduct of the study.
The results
Once a study is complete, researchers analyze the results to see if the investigational therapy was inferior, equivalent, or superior to the standard of care. The difference in results, if any, is determined by comparing the statistical significance of changes in the study endpoints between the study group and the control group. For example, if the study endpoint was a change in viral load, investigators may ask, "What was the average change in the study group's viral load compared to the control group's? Is this difference statistically significant?"
Since the volunteers in both groups shared similar characteristics at the start of the study, their baseline viral loads should have been about equal. And since they were assigned by chance to either the study group or control group, any significant changes at the end of the study in their viral loads should be attributable to the treatment they received--the treatment being the only difference between them. If, at the end of the study, the viral loads of the 2 groups are roughly the same, the researchers may conclude that the new therapy is equivalent to existing treatments: no better, no worse.
If the viral load of the study group is significantly lower, statistically speaking, than that of the control group, the researchers may conclude that the new treatment is superior to existing treatments. There is a potential catch, however. All statistically significant changes are not necessarily clinically significant. In other words, a statistically significant difference may not actually matter for the health of patients. To see why, consider this analogy. Suppose researchers offer 2 groups of 100 patients a drug designed to increase their earning power. Suppose that at the end of the trial, the study group has earned 5 cents and the control group has earned only 1 cent. Is this difference statistically significant? Yes, it is. But is it economically significant? No, not really. In the US economy, whether people have a nickel or a penny matters very little. Either way, they aren't buying much. Similarly, changes between groups in viral load could be statistically significant without being clinically significant.
Also, changes in viral load or CD4 T cell count do not tell the whole story. Other important considerations are a drug's convenience, tolerability, and safety. Say an investigational drug dramatically reduced viral load but had to be taken 5 times a day on an empty stomach, caused severe nausea, and put the patient at increased risk for liver cancer? Is it a good drug?
Often investigators examine the difference between a drug's treatment effect (its ability to reduce viral load or raise T cell count) and its clinical effect (which includes convenience and tolerability) by performing 2 sets of analysis. In one type of analysis known as on treatment, researchers consider only the treatment effect of a drug and count only those patients who actually take the medication. In other words, if a patient stays on treatment, regardless of side effects or inconvenience, how well does the medication affect the surrogate markers? In another type of analysis, known as intent to treat, researchers include the consequences of a drug's side effects and dosing schedule and count all the patients in a study, whether they take the medication or not. The difference in results between these 2 types of analysis can be sharp.
Say 500 hundred patients are given experimental drug A. If 250 of them take the drug faithfully and it lowers their viral loads to undetectable, an on-treatment analysis will show 100% efficacy, even though the other half of the patients did not take the drug because it made them sick. On the other hand, an intent-to-treat analysis--designed to capture the "real world" results of a medication--will count all the patients, including those who couldn't stomach the drug's side effects. By this method, the experimental drug will show efficacy of 50%, having been credited for working only in those patients who could take it.
For patients deciding whether to participate in a clinical trial, it is important to know what phase of study the drug is in and whether those who are assigned to the control arm will receive a placebo or standard of care. Also, will the study be blinded or open label? In other words, will the volunteers know what arm of the study they are in? In a blinded trial, the volunteers are not told whether they are in the study arm or the control arm. In an open-label trial, they know. Blinded trials adjust for bias on the part of study volunteers--for example, when volunteers report side effects caused by the medication even though they're actually receiving a sugar pill--but blinded trials also increase the uncertainty of participating in a study.
Another key question is, "What exactly do the researchers hope to learn from this trial?" At the heart of every clinical trial, regardless of the phase of study, there is a scientific question. Informed study volunteers find out what the question is and decide for themselves whether they think it is worth answering. The informed consent document explains the purpose of the study as well as the risks and benefits the study offers to volunteers.
In reviewing the results of a clinical trial, it is important to know what population of patients the study included. The results of a study can only be generalized to patients who share the characteristics of the study volunteers. For example, if a study included only volunteers who were naive to anti-HIV drugs, the results cannot be generalized to patients who are heavily experienced with anti-HIV drugs. Similarly, a drug that produces good results in volunteers who started out with 500 CD4 T cells may not work as well in patients whose T cell counts are less than 100. The characteristics of the patients who participated in the study are determined by reviewing the inclusion/exclusion criteria.
Finally, an essential issue is whether the results of a study are not only statistically significant, but also clinically significant. What endpoints did the researchers use for evaluating a drug's efficacy? Are results reported from an on-treatment analysis or an intent-to-treat analysis? Clinical trials are most helpful when they ask important questions, are well designed, recruit informed volunteers, and report clinically meaningful information.
Phases 1 to 3: Clinical studies are usually divided into 3 phases, with each phase serving to answer a specific question about an investigational therapy.
Study volunteers: In the context of HIV clinical research, study volunteers are men and women with HIV infection who meet a study's inclusion/exclusion criteria and agree to participate in the trial.
Surrogate markers: Laboratory tests, usually CD4 T cell count and viral load, that are used to estimate the health benefit of an investigational drug.
Study endpoints: The measures used to determine whether an investigational drug works. In HIV clinical research, the study endpoints are usually a change in surrogate markers.
Control group: A group of patients in a study who receive a "sugar pill" or conventional treatment rather than the experimental therapy. A control group is necessary to determine whether an investigational drug offers any benefit over existing therapies.
Placebo: The formal name for a "sugar pill." An inactive substance.
Standard of care: The level or type of care generally given to people with a particular condition.
Study group: A group of patients in a study who receive the experimental drug.
Inclusion/exclusion criteria: The list of characteristics that define who may and may not participate in a clinical study.
Protocol: A written description of a study and a guide to its conduct. Protocols are usually lengthy documents, sometimes running hundreds of pages in length.
Baseline: Refers to anything present at the start of a study. For example, if a patient enters a study with a viral load of 50,000 copies, this is the baseline viral load.
Treatment effect: The effect of an investigational drug on study endpoints, e.g. viral load or CD4 T cell count.
Clinical effect: The effect of an investigational drug on factors other than the study endpoints, including, for example, quality of life.
On treatment: A type of analysis in which researchers count only those patients who actually took the investigational drug for the study duration. This type of analysis excludes patients who failed to take the medicine, whether or not they had a good reason for doing so. On-treatment analysis is best for determining the treatment effect of a new therapy.
Intent to treat: A type of analysis in which researchers count every patient who participated in the study of an investigational drug. This type of analysis includes patients who failed to take the medicine, whether or not they had a good reason for doing so. Intent-to-treat analysis is best for determining the clinical effect of a new therapy.
Blinded: A type of study in which the volunteers are not told whether they are receiving the investigational drug or standard of care. If even the doctor does not know which patients are receiving the investigational drug, the study is called "double blinded." Blinded studies help to reduce bias.
Open label: A type of study in which the volunteers are told whether they are receiving the investigational drug or standard of care.
Informed consent: A document that explains, in easy-to-understand language, the purpose of a study and the risks and benefits it offers for volunteers. Every volunteer in a study should receive a copy of the informed consent document.
Generalized: The act of having taken results from a study and applied them to people who did not actually participate in the study. Results from a clinical trial may be generalized only to patients who share the characteristics of the study volunteers, e.g. similar viral loads or treatment history.
RELATED ARTICLE: How do they do that?
A look at structure-based drug design
Where do potential anti-HIV drugs come from in the first place? Before any drug candidate reaches clinical trial, researchers must first identify and test it in laboratory studies. How do scientists find these candidates, and what's the process for testing them?
HIV has 3 enzymes that perform important work for the virus. (An enzyme is a protein that catalyzes, or facilitates, chemical reactions.) These enzymes are targets for therapy, and to date researchers have identified and successfully tested inhibitors of two of HIV's enzymes, namely reverse transcriptase and protease. But an inhibitor of the third enzyme, integrase, has so far eluded researchers. Several research groups are still looking for an integrase inhibitor, including one at the University of Houston, led by Kurt Krause, MD, PhD.
To find an inhibitor for a viral enzyme, researchers start by studying the structure of the enzyme itself. Using sophisticated technology, samples of the enzyme are examined to determine its shape and to identify the point where an inhibitor might attach. This point is known as the "active site." Once the structure of the enzyme is identified, that information is fed into a computer which sorts through a database of hundreds of thousands of small molecules, looking for one that fits the enzyme. Several of these "virtual" molecules might fit, some better than others. The computer scores a molecule's affinity for the enzyme, ranking it as high, medium, or low. A high-affinity molecule may become a "lead compound," at which point chemists begin to make it. Other scientists will then test the lead compound in the laboratory against actual viral enzymes. (See Figure.)
If it works, the molecule will undergo further testing to estimate whether it is safe for humans to receive, and if so, whether it is bioavailable. (Bioavailability refers to how well a drug is absorbed by the human body.)
According to Krause, the problem with finding an inhibitor for HIV integrase is two-fold. First, the structure of the integrase protein complex isn't fully understood, and the "active site" where a drug might attach is shallow. Reverse transcriptase, in contrast, has a shape similar to a hand with the fingers drawn in, and the palm--the active site--serves as a deep pocket to which drug can stick.
In the coming years, Krause (who is also interested in finding treatments for other infectious diseases, including tuberculosis) estimates that advances in technology and improvements in efficiency will reduce the cost of drug discovery by several million dollars. This should help to reduce the cost of treatments and make them more widely available, especially in the developing world.
|Printer friendly Cite/link Email Feedback
|Simmons, Paul
|Research Initiative/Treatment Action!
|Jun 22, 2002
|Previous Article:
|Letter from the editor.
|Next Article:
|An overview of the drug approval process. (FDA Overview).
|Betaseron bulletin.
|The what's and why's of clinical trials.


text:
For the 13th annual Tewaaraton Awards presentation. Though Rob Pannell of Cornell took home the trophy, awarded annually to the top male and female collegiate lacrosse players in the U.S., Thompson says he was honored to be among the five male finalists. He is the first Native American to be named a Tewaaraton finalist.
A member of the Onondaga Nation, Thompson was named the America East Player of the Year, a first team All-American and took home the 2013 United States Inside Lacrosse Association Lt. Col. J.L. (Jack) Turnbull Award for being the top NCAA Division I attackman this year. Thompson, only a sophmore at the University at Albany, led the nation in scoring this season, racking up 113 points on 50 goals and 63 assists, which was two points shy of breaking the all-time NCAA record set by Steve Marahol (114 points in 1992). He was the nation's leader in points per game with 6.65, which is the 13th highest points per game for an individual in NCAA history.
One thing that makes Thompson's time even more special at UAlbany is that he gets to play with family: Brother Miles and cousin Ty. The Thompson Trio was a special attack group overall this past season Lyle, Miles and Ty tallied the nation's highest point total as a starting attack group with 259 points. (Watch: NCAA on Campus: the UAlbany Thompson LAX Family)The next closest attacking group is Cornell's Tewaaraton Award-winning Pannell, Steve Mock and Matt Donovan with 196. Both Miles and Ty were named honorable mention All-Americans.
During the Tewaaraton Awards ceremony, hosted by the Smithsonian National Museum of the American Indian, ICTMN caught up with Thompson to talk about the Creator's game. (Watch an ICTMN exclusive video: Lyle Thompson talks about the Creator's game at the Tewaaraton Awards ceremony in Washington, D.C. on May 30.)
How long have you been playing lacrosse?
I don't know, I was maybe two or one when I started. I look at my nephew, my brother's son, and he is already trying to scoop up a ball and passing it. He is only 18 months. I have been playing organized lacrosse since I was seven years old. But, as soon as I could pick up a lacrosse stick and I could walk, I was playing around with my stick, and throwing the ball around with my brothers.
Is lacrosse more than a game?
Every game I play, I am thinking about traditions, the Creator and why I am playing this game. Before every game and after every game I am just thankful to be playing the Creator's game.
Do you attribute any of your lacrosse success to being a Native American?
I think it is more about when you're growing up and you are playing lacrosse your whole life, it is more just that than being Native American. I guess, in a way it is an advantage because to us it is a lifestyle and not just a game.
How does it feel to be named one of the top five male collegiate lacrosse players in the country?
It is just an honor and I never really thought about how big of a deal this is. Once I came into this museum and began looking around at all of the other Native American stuff here, it makes me realize this is big and it is an honor just to be a finalist. Just looking at it and knowing it is Native American art…it just means more to me now.
Have you had a chance to reflect on your season?
I was just thinking about my year, and the other day I was talking about it with my brother and getting All-World best midfielder [editor's note: Lyle was named to the All-World Team at the Federation of International Lacrosse 2012 U19 World Championships, at which he helped lead the Iroquois Nationals to a phenomenal bronze medal-winning result, beating the U.S. along the way] and coming here and just processing what I have accomplished this year, I am just grateful and honored to play the game and be here.
Do you have any words of advice for young lacrosse players just getting started?
I kind of took this from Michael Jordan, but, "learn to love the game." Once you love the game, it just takes you on to another level of accomplishments and you try harder. It is just more than a game when you love it, and you love it so much that you are willing to do anything to have fun and be successful.


text:
Holly Black and Cecil Castellucci's opening story "had me at hello" - just uproariously funny. Libba Bray's story and my new hero "David Leithan" - were amazing. I will confess there were some great stories and some not-so-great one's - but in the end I think it was a good all-around package. I really wasn't much of a geek during high school and at one point even doubted whether or not I was geek enough to get some of these stories- but other than a handful of references that went over my head - I felt right at home.
This is great reading for those of us who at one point were obsessed with Klingons, Jedis, Dr. Who, astronomy, dinosaurs, drama club, marching band, crushes, Rocky Horror Picture Show, Quiz Bowl, etc.
This is a must read for any geek, geeklover, or undercover geek. I'm totally doing the "live long and prosper hand signal" right now.
Rules: This contest is open to U.S. & Canada residents only. No P.O. Boxes. Winners will be drawn Wednesday, September 30.


text:
My Account
Contact Us
About Our Store
News & Features
Reference Room
Health Calculators
Conditions & Allergies
Health & Wellness
Vitamins & Minerals
Functional Foods
Children's Health
Adolescent's Health
Women's Health
Men's Health
Senior's Health
Healthy Recipes
Ingredient Glossary
Delicious Living
Cone's Links
Table of Contents
> Brentuximab Vedotin
Brentuximab Vedotin
Related terms
Author information
Related terms
Brand Names: U.S.
: AdcetrisT
It is used to treat lymphoma.
Brentuximab harms cells causing their death.
How to take
It is given as a shot into a vein over a period of time.
This drug may rarely cause a very bad brain infection called PML (progressive multifocal leukoencephalopathy). People with a weak immune systems have more chance of getting this infection. Read the part in this leaflet which tells you when to call your doctor.
Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.
If you have an allergy to brentuximab vedotin or any other part of this drug.
Tell your doctor if you are allergic to any drugs. Make sure to tell about the allergy and what signs you had. This includes telling about rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
If you are pregnant or may be pregnant.
If you are breast-feeding.
Have your blood work checked. Talk with your doctor.
Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.
Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.
Use birth control that you can trust to stop pregnancy while taking this drug and for up to 12 months after this drug.
Side Effects
Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.
Anemia, low white blood cell count, and low platelet count.
Feeling tired or weak.
Muscle or joint pain.
Numbness and tingling.
Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.
Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.
Belly pain.
Hard stools (constipation).
Loose stools (diarrhea).
Brain infection may rarely happen.
Contact a healthcare provider
Signs of a very bad reaction to the drug. These include wheezing; chest tightness; fever; itching; bad cough; blue or gray skin color; seizures; or swelling of face, lips, tongue, or throat.
Signs of infection. These include a fever of 100.5°F (38°C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.
Change in the way you act.
Change in thinking clearly and with logic.
Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.
Very bad dizziness or passing out.
Feeling very tired or weak.
Very bad headache.
Very upset stomach or throwing up.
Very bad belly pain.
Very loose stools (diarrhea).
Numbness or tingling in your hands or feet.
Any bruising or bleeding.
Very bad skin irritation.
Any rash.
Side effect or health problem is not better or you are feeling worse.
General Statements
If you have a very bad allergy, wear an allergy ID at all times.
Do not share your drugs with others and do not take anyone else's drugs.
Keep all drugs out of the reach of children and pets.
Most drugs may be thrown away in household trash after mixing with coffee grounds or kitty litter and sealing in a plastic bag.
In Canada, take any unused drugs to the pharmacy. Also, visit http://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.
Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
Call your doctor for help with any side effects. If in the U.S., you may also call the FDA at 1-800-FDA-1088 or if in Canada, you may also call Health Canada's Vigilance Program at 1-866-234-2345.
Talk with the doctor before starting any new drug, including OTC, natural products, or vitamins.
Author information
Copyright © 1978-2013 Lexi-Comp Inc. All rights reserved.
Copyright © 2011 Natural Standard (
The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.
Search Site
Entire Site
Reference Room
Healthy Recipes
News & Features
About Our Store
Reference Room
Cone's Links
My Email Subscription
Contact Us
Privacy Policy
Terms of Use
All contents © Copyright 1999-2019 Genius Central and Cone's Health Foods. All rights reserved. This internet site is hosted by Genius Central, a Web site service provider to natural health stores nationwide. Genius Central and Cone's Health Foods have no means of independently evaluating the safety or functionality of the products offered by their suppliers and affiliates and thus can neither endorse nor recommend products. Information presented is of a general nature for educational and informational purposes only. Statements about products and health conditions have not been evaluated by the US Food and Drug Administration. Products and information presented herein are not intended to diagnose, treat, cure, or prevent disease. If you have any concerns about your own health, you should always consult with a physician or other healthcare professional. Your use of this site indicates your agreement to be bound by our
Terms and Conditions
Cone's Health Foods
8200 Stockdale Hwy
Suite B-3
Bakersfield, CA 93311
(661) 832-5669
Monthly Newsletter
Enter your e-mail address into the field below to subscribe to our monthly newsletter.
Social Networking
Copyright © Cone's Health Foods. All rights reserved.


text:
The New York Film Festival returns for a 43rd edition this fall offering a program of 24 features on its roster, in addition to a number of special screenings. After opening with the previously announced "Good Night, And Good Luck" by George Clooney, the festival will continue through October 9, 2005 when it will close with Michael Haneke's "Cache" (Hidden), a hit at this year's Cannes Film Festival where it was acquired by Sony Pictures Classics. Neil Jordan's "Breakfast on Pluto", starring Cillian Murphy as an Irish transvestite who moves to London in search of a lost parent (also from Sony Classics) is this year's Centerpiece screening at the NYFF.
On the list for 2005 are a trip of titles from South Korea, including the latest from Im Sang-Soo ("The President's Last Bang"), Park Chan-Wook ("Sympathy For Lady Vengeance") and Hong Sang-Soo ("A Tale Of Cinema"). The films mark the continuing strength of films from that country, explained Richard Peña in an email conversation with indieWIRE Wednesday.
"Certainly we were all pleased to be able to present three South Korean films in the NYFF this year," said Peña, the Festival's committee chairman and Film Society Program director. "The emergence of South Korea as a major filmmaking venue has been apparent for at least a decade now, and this year for me it was as if that national cinema has reached an even more impressive level of achievement, with three films that are enormously different from each other yet each brilliantly realized."
Peña also emphasized the significance of work from Eastern Europe. "We were also pleased to see what seems to us like a re-emergence of Eastern Europe at the NYFF, with wonderful new films from Romania, Poland and the Czech Republic." Among the entries include Cristi Puiu's "The Death of Mr. Lawrence (Romania), Dorota Kedzierzawska's "I Am" (Poland), and Bohdan Slama's "Something Like Happiness (Czech Republic).
Other members of the 2005 New York Film Festival selection committee included Kent Jones, Film Comment magazine editor-at-large and Film Society associate program director; author and critic Phillip Lopate; John Powers, critic-at-large from NPR, Village Voice, and L.A. Weekly; and Lisa Schwarzbaum, film critic for "Entertainment Weekly".
Among the special programs on tap for this year's festival are a number of live discussions, including a panel entitled "Speaking Truth to Power: Media, Politics, and Government," pegged to the opening night screening of Clooney's "Good Night, And Good Luck" about newsman Edward R. Murrow's battles against Sen. Joseph McCarthy in the 1950s. Brian Lehrer, Don Hewitt, Helen Thomas are already booked to discuss the topic. Also on tap is the HBO Directors' Dialogues, with Neil Jordan already booked, and a Film Comment Focus program with actor Steve Coogan.
"What's that old Bob Dylan line?" offered Peña, when asked about what seem to be an increasing number of special events at the annual New York Film Festival "'He not busy being born is busy dying'. Like any cultural organization, or maybe just any organization, we're constantly assessing what we do right and what we could do better."
Peña noted that the perceived changes in the festival havecome about to address needs in the program. "The NYFF is ahigh-profile time for the Film Society, so we try to usethat media attention to highlight something we'd especiallylike to highlight, such as our tribute to Shochiku thisyear," Peña added, referring to a 44-film retrospectiveof the work of Japan's noted studio.
The annual New York Film Festival, at times regarded as stodgy or old school, remains a highly curated event showcasing a small number of movies with evening screenings. It's a formula that runs counter to the many festivals vying for audiences and industry, especially in the busy fall season. When asked yesterday to share his sense of the state of film festivals today, and whether the role of the festival itself has changed, Peña noted, "The state of film festivals seems somewhat precarious. At their best, festivals should be crossroads, where critics, scholars, filmmakers, distributors and the general public can meet to get a sense of what's happening in the medium. too often I feel that festivals in general are becoming worlds unto themselves, with little connection to anything else. I think that's not a good trend."
Continuing he offered, "The role of festivals has indeed changed, because the market has become that much more competitive, with far more releases than ever before, so to get a slot in what are considered the key festivals is even more important for a foreign language or independent film." And he concluded in the email conversation with indieWIRE, "There's also the fact that in many places festivals are the only way that communities will ever get to see many of the these films, as the 'art cinema' presence has dwindled so much in recent years."
2005 New York Film Festival Lineup:
Opening Night:
"Good Night, And Good Luck", directed by George Clooney, USA (Warner Independent Pictures)
"Breakfast On Pluto", directed by Neil Jordan, USA (Sony Pictures Classics)
Closing Night:
"Cache" (Hidden), directed by Michael Haneke, France (Sony Pictures Classics)
"Avenge But One Of My Two Eyes", directed by Avi Mograbi, Israel/France
"Bubble", directed by Steven Soderbergh, USA (Magnolia Pictures)
"Capote," directed by Bennett Miller, USA (Sony Pictures Classics)
"The Death Of Mr. Lazarescu", directed by Cristi Puiu, Romania (Tartan Films.)
"L'enfant" (The Child), directed by Jean-Pierre And Luc Dardenne, Belgium/France (Sony Pictures Classics)
"Gabrielle," directed by Patrice Chereau, France
"I Am," directed by Dorota Kedzierzawska, Poland
"Manderlay", directed by Lars Von Trier, Denmark/Sweden/France (IFC Films)
"Methadonia", directed by Michel Negroponte, USA (HBO Documentary Films)
"Paradise Now", directed by Hany Abu-Assad, Netherlands/German/France (Warner Independent Pictures)
"The President's Last Bang", directed by Im Sang-Soo, South Korea (Kino International)
"Regular Lovers", directed by Philippe Garrel, France
"Something Like Happiness", directed by Bohdan Slama, Czech Republic
"The Squid And The Whale", directed by Noah Baumbach, USA (Samuel Goldwyn Films / Sony Pictures Entertainment)
"The Sun," directed by Aleksandr Sokurov, Russia/Italy/France/Switzerland
"Sympathy For Lady Vengeance", directed by Park Chan-Wook, South Korea (Tartan Films)
"A Tale Of Cinema," directed by Hong Sang-Soo, South Korea/France
"Three Times," directed by Hou Hsiao-Hsien, Taiwan
"Through The Forest", directed by Jean-Paul Civeyrac, France
"Tristram Shandy: A Cock And Bull Story", directed by Michael Winterbottom, UK (Picturehouse Films)
"Who's Camus Anyway?", directed by Mitsuo Yanagimachi (Japan)
Special Screenings:
"The Beauty Of The Everyday: Japan's Shochiku Company At110"
A 44-Film Retrospective Spanning The Seminal Japanese Studio's Storied History.
"Beyond The Rocks," directed by Sam Wood, USA (Milestone Films) "Greeneland". Illustrated Lecture with Clips, by Adrian Wooten On Cinematic Work Of Graham Greene.
"Haze," directed by Shinya Tsukamoto, Japan. Midnite Screening.
"Nezumi Kozo," directed by Noda Hideki, Japan. DLP Cinema Hi-Def Presentation, With Performer Nakamura Kankuko In Attendance. A Shochiku Retrospective Special Event.
"The Passenger," directed by Michelangelo Antonioni, Italy/USA/France. New Print Of Antonioni's Preferred Cut. (Sony Pictures Classics)
Views From The Avant-Garde. Experimental Works By Various Filmmakers.
Sign Up: Stay on top of the latest breaking film and TV news! Sign up for our Email Newsletters here.


text:
The University of Illinois at Urbana-Champaign is a public research institution founded in 1867 and is one of the original 37 public land grant universities established after President Abraham Lincoln's enactment of the Morrill Act in 1862. It is in the twin cities of Champaign and Urbana, about 140 miles south of Chicago. The university is home to more than 32,000 undergraduate and more than 12,000 graduate students from all 50 states and several countries, and it employs more than 6,000 faculty and staff members. It comprises 17 colleges and instructional units and has one of the largest public university libraries in the world, with more than 24 million items.
The University of Illinois' Alma Mater statue.


text:
Assist me with Bulk Marketing
Presupuesto $10-30 USD
Find a users for "online patent" services.
The task of the project is to find a user for me who will use the services of the "online patent", by my recommendation will get a 5% discount in the "Online Patent".
Who finds for me a real user and who will take advantage of the "Online patent" services will get the award. I will pay your award after the user pay services in the "Online Patent".
I hope to develop business and partnership with you to provide "online patent" services.
I propose a version of the interaction on completion for each of our transactions:
You execute the project and receive your bid but for the duration of the project you need the new user to pay for his service in the "online patent" and then we are guaranteed to have completed the transaction with you.
Please, contact me for the advantageous relationship for you.
Do you find a user for "online patent" services?
Do you accept the conditions that guarantee me success and your bid-win in the project?
7 freelancers están ofertando el promedio de $63 para este trabajo
Hello, I am independent sEO expert offer a refreshingly transparent and strategic approach to online success through sound Search Engine Optimization. Our search marketing solutions provide quantifiable, measurable Más
Hi I am Sonu independent SEO Freelancer. I only have one goal – getting YOU, the customer, to the top of leading search engines like Google, bringing you more traffic to your website and keeping you there with our Más
HELLO I CAN START RIGHT NOW - I AM EXPERT IN Advertising Bulk Marketing and I BET YOU CANNOT FIND BETTER FREELANCER THAN ME ... pLEASE MESSEGE ME AND LETS DISCUSS THE THINGS THANKS
Dear Prospect Hiring Manager. Thank you for giving me a chance to bid on your project. i am a serious bidder here and i have already worked on a similar project before and can deliver as u have mentioned I have Más
Hi... I have a team of professionals,that satisfy your needs & meet beyond your expectations. I bid your project only because I sure 100% we can do this project. What we do for you: On-Page Optimization->Meta Más
We offer best email marketing services and best prices. Features: - cloud email campaining management platform - IP rotation system - multiple IPs and domains - PowerMTA management - Return Path cer Más


text:
Reviewed by DaVon S. (age 14)
The plot captivated me and I really enjoyed when Matt escaped 146 year old El Patron, the Employer. Matt was the only character in the story to change and develop. Initially, he was a little boy searching for a father figure, but soon discovered that he must become his own person. There is so much action and suspense that I think the story would make a great movie. At times, it leaves you breathless!
I would recommend this book to anyone who likes science fiction or who just enjoys an interesting story. It would be well worth the read.


text:
|Frequently Asked Questions
We answer e-mails almost every day, and answer many questions time and time again. Please see most of the common questions that we answer in the faq. If your question is not answered here, please contact us!
Will the fruit and vegetable juicers juice citrus?
Citrus fruits, such as oranges, grapefruits, tangerines, have a bitter outer rind, and juice from a "whole" orange would be too bitter to drink. It also contains indigestible chemicals. One solution is to grate away the outer rind (the orange coloring on the orange - it is best to leave the white "pith", as valuable nutrients are contained within the white area). The more common method, is to slice the fruit in half, and then using a "reamer" style juicer or a citrus press to press out the juice.
Home | Juicers | Wheatgrass Juicers | Citrus Juicers | Blenders | Water Purifiers


text:
Best Practices for Virtual Committee Work
From ALSC
(Redirected from Best Practices for Virtual Committee Work - UNDER CONSTRUCTION)
General Tips and Advice for Virtual Collaboration
Practical tips for leading virtual teams.
Frequently asked questions about working on a virtual committee.
Getting the Most out of ALA Connect
ALA Connect is the key to your virtual committee's success. Learn how here!
Online Tools
Tools to help you accomplish your committee work virtually, including tools for Scheduling, Calendars, and Task Tracking, Project Collaboration, Meetings and Communication, Idea Sharing, and the ALSC Wiki.
Best Practices Forum for Discussion on ALA Connect
A community on ALA Connect where committees will share experiences, ideas and tips related to virtual committee functioning.
Return to the Main Page


text:
Whatever skepticism we may have about the Tesla Model X, no one here believes the goals of environmental improvement and driving fun are necessarily contradictory. This ad for Mazda's new SKYACTIV-G technology basically sums that up better than anything I've seen.
Seriously. This may crack into the top ten car advertisements I've ever seen. It's got a lo-fi feel with a mix of some modern shots tossed in to a vintage b-roll salad. And Bo Diddley. Check Bo out, man. I dig it.
Who cares that this ad features clips of people driving Chevys and video of the 787 that, for all we know, was pulled from Forza 4? It translates exactly what I want to feel about environmental technology.
Also, it's probably all that Mazda could afford given their $1.3 billion loss for the fiscal year. That's maybe why I didn't see this ad on television, but on Hulu, between episodes of a show I'm not going to admit that I watch.


text:
Levi Johnston, now invading your televisions
Levi Johnston, now invading your televisions
I suppose this was inevitable. Levi Johnston is shopping around his very own "Jersey Shore" style reality show. What could go wrong?
Levi Johnston, Sarah Palin's grandbaby-daddy and the bane of her existence, is pitching his own docu-series in which he will introduce viewers to Alaska.
The news comes just days after Discovery Networks announced that its TLC network would air "Sarah Palin's Alaska" in which she will introduce us to Alaska.
… Levi's show, tentatively titled "Levi Johnston's Final Frontier," is " 'Jersey Shore' on ice," Krasnow said.
… Levi and his pals "put jet fuel in their snowmobiles — they trick them out," the producer said. "They drive Ford pickups. They don't go on the Internet often. That's what we're interested in about him."
… The aspiring reality TV star and his party-mobile were making stops at various cable networks' offices to pitch a series that Krasnow hopes will be around eight episodes — just like Palin's.
Monday afternoon, the Johnston party wagon was parked outside MTV Networks' offices in Santa Monica.
Krasnow, whose credits include "The Weakest Link," would not confirm what other, non-MTV, networks were being pitched, other than to say they were all networks that target "younger-skewing networks" — networks that attract "the type [of viewer] that would not watch TLC or Discovery."
Exact details of Levi's show were being kept deliberately vague, so the project could be tailor-made to suit the purchasing network.
Mothership MTV network, for instance, might want to focus more on Levi's first time on the dating scene in Alaska since breaking up with Bristol, whereas MTV's Spike network might want them to focus on what Krasnow called "the adrenaline activities he has in Alaska with his buddies."
… "He's a 19-year-old kid living a life like nobody else's on the planet and in the culture of Alaska — that interested us. When Sarah Palin made her announcement, we rushed and decided to go out quicker. In a competitive marketplace, it made sense, if Sarah Palin is going to try to own Alaska," Krasnow snarked.
"She may try to tell us how beautiful an iceberg is. . . . His version might include skinning a bear."
That said, Krasnow said he's going to do a show "that's authentic and real — it's not trying to just be some anti-Sarah Palin show. That is not our motivation. We're showing Alaska through somebody else's eyes — the lives of real people in Alaska — and throwing into the limelight a good guy who is poised and polite; a good kid."
Yeah — a good, poised, polite guy who impregnates a girl, leaves her, refuses to pay child support, jet-sets between Hollywood and New York trying to become a celebrity, and poses in Playgirl. A "Jersey Shore" style reality show sounds about as classy as he is, and so it sounds perfect for him.
While I guess this would technically be considered a good thing for his son — this would certainly help him with the child support — I still can't help but think deadbeat dad over and over again when I think of Levi Johnston. Bristol is a teenager, too. She's got notoriety just as much as Levi does. Yet you don't see her out there milking it for every penny its worth. Sure, she does a TV appearance here and there, but Levi takes it to a whole other level. He's walking the red carpet at celebrity parties, posing naked for Playgirl, hiring a manager and a bodyguard, inventing a ridiculous new name for himself, all while Bristol stays home in Alaska and takes care of their son. They aren't a couple anymore, but he still has a responsibility to be a father to his son. And judging by the content of this reality show — jet fuel in snowmobiles, "lots and lots of women", as reported by Newser — it seems like being a good father is the last thing on Levi Johnston's mind. He wants to exploit the publicity he found due to briefly being a part of the Palin family, and now he's turned his back on them. At least Bristol is taking responsibility for her actions. Levi is exploiting his son and the mother of his child to try to become a celebrity. I somehow doubt Tripp will be particularly proud of his father when he grows up. Levi, meanwhile, doesn't seem to realize that he's a Hollywood laughingstock.
As far as the battle between Sarah and Levi, it seems to me that Alaskans will prefer Sarah's version by far. It looks as if Levi is out to make young Alaskans look like nothing more than idiotic, adrenaline-seeking hicks. Sarah Palin is out to show the beauty and the adventure of Alaska. Which was seems to be a more positive representation? If anything, I'd imagine that Levi's show will be an embarassment to Alaskans, and especially the community of Wasilla.
Happily, I have no doubt that the real loser in all of this won't be anyone else but Levi Johnston. If he does do this reality show, then it will do nothing but show him for the low-class piece of trash he is.
Cross-posted at The Green Room.
this would certainly help him with the child support
Yes. Yes, it would.
Looks like he's given up on the Ricky Hollywood nom de clown now.
"Levi Johnston, Sarah Palin's grandbaby-daddy and the bane of her existence…"
Riiiight. I am so sure that Sarah goes to sleep every night saying to herself "One day I'll get him! Oh yes, He will PAY!!!!" and then she laughs an evil laugh.
Right, sure she does.
I thought that this part was the best:
"She may try to tell us how beautiful an iceberg is. . . . His version might include skinning a bear."
Sarah can field-dress a moose and has hunted for her own food. Levi Johnson has so far only shown himself capable of taking his clothes off.
The other losers in this will be the network that's paying for all this; no way in hell will they ever be able to recover their money. Aside from the fact that most teenagers – even the mature, well-informed ones – simply cannot be television-worthy ambassadors to their states, Levi is, from all appearances, too much of a moron to manage this. Perhaps someone else will spoon-feed him the script, but good luck getting anyone to watch it.
Now, my rant: this man is a FATHER. He needs to start acting like one, which means keeping his clothes on, supporting his son (both financially and emotionally), and, as practicable, helping Bristol to raise a son.
Levi will do nothing but show a generation of young men that fatherhood is the route to fame, and that women – even when they don't abort – are still disposable. Bastard.
I'm so sick of this guy. He's just one entry on a long list of people whose fifteen minutes of fame were up a long time ago.
I'm sure one of Cassy's frequent posters (who shall remain nameless) will be along any minute now to remind us that Palin is "damaged goods" because of this classless moron and his ceaseless publicity stunts.


text:
- This event has passed.
Worship: Catholic Mass
October 13, 2018 @ 5:00 pm - 6:00 pm
|Recurring Event (See all)
An event every week that begins at 5:00 pm on Saturday, repeating until December 30, 2018
Weekly Roman Catholic mass held in the sanctuary of Saint Paul. Presided by Pastor Don Sutton.


text:
Car Review
2012 Toyota Camry Hybrid: New Car Review
With significantly higher fuel economy, incredible value, multiple trim levels to choose from and the same Camry comfort as its non-hybrid brethren, the 2012 Camry Hybrid is an easy choice for the modern family, reflecting the growing acceptance of hybrids among the car-buying public.
New for 2012 is an LE version of the Camry Hybrid. The Camry Hybrid LE comes nicely equipped including auto on/off halogen headlamps, front and rear disc-brakes, Bluetooth connectivity, a six-speaker audio system with USB port, remote keyless entry with push-button start, dual zone automatic climate control, 6-way adjustable driver seat, cruise control, and power windows with auto up/down.
The upgraded Hybrid XLE trim adds rear seat vents to the climate control system, an upgraded audio system with a 6.1 inch touchscreen, expanded Bluetooth capabilities such as music streaming, an 8-way adjustable driver seat, steering wheel-mounted audio and Bluetooth controls, fog lamps, and larger 17-inch alloy wheels.
As with all 2012 Camrys the front seats suffer from a lack of bolstering. Simply put, the seats don't do a great job of holding occupants in place during hard cornering. The only category in which the Camry Hybrid loses points compared to the non-hybrid is in trunk capacity. Given that the batteries are stored there, the hybrid trunk is a full 2 cubic feet smaller-roughly 15 percent-than in the non-hybrid.
Upgrades on the tech front include optional features such as Toyota's new Entune entertainment and internet search system, navigation, satellite radio, backup camera and integrated HomeLink garage door opener. Entune works well and includes such applications as Pandora Internet radio and Bing search. If you're into that kind of stuff, you'll need to opt for the Hybrid XLE because those items can't be added to the Hybrid LE.
Performance and Fuel Economy
With an EPA rating of 39 mpg highway and 43 city, the 2012 Camry Hybrid LE delivers nearly 30 percent better fuel economy compared to the outgoing model. Even with its fuel sipping behavior, the new powertrain puts out 200 horsepower, a 13 horsepower increase.
Toyota was able to achieve this feat by tweaking the same 2.5-liter, four-cylinder engine found on the base Camry and mating it to their time-tested hybrid system. Additional gains come from a new feature that sends exhaust gas back through the engine to be burned again. The end result of this Exhaust Gas Recirculation system (EGR) is lower emissions and increased fuel efficiency.
While the Hybrid XLE is rated at a lower, but still stellar, 38 highway and 40 city mpg, over the course of our day's worth of test driving in that model we were able to achieve 43 mpg in mixed driving conditions without really trying by engaging the ECO mode. As is the case with all cars that rely at least in part on electricity, mileage can vary quite a bit based on driving habits.
Ride and Handling
While the 2012 Camry Hybrid adds much in the way of increased fuel economy, it doesn't seem to sacrifice much when compared to the non-hybrids. Handling is on par with our four-cylinder non-hybrid XLE tester-perhaps even slightly enhanced due to the better distribution of weight between the front and rear axles from the placement of the battery in the trunk. The Camry Hybrid's CVT-a transmission usually associated with uninspired performance-felt more refined than in past models.
Acceleration is also brisk compared to the four-cylinder model. However, you can still feel the gasoline engine kicking in as the car transitions from electric drive to gas/electric. It's not as pronounced as in the previous Camry Hybrid but that somewhat odd driving dynamic isn't totally gone. There's also a good deal of whine from the regenerative brakes. It seems a little more pronounced than before but that regenerative system now adds juice back to the battery over a wider range of braking conditions. Thankfully, the Camry Hybrid's brakes are not grabby as with some other hybrids.
In years past, Toyota has positioned the Camry Hybrid as an upscale trim level within the Camry lineup, typically viewing it as a green alternative to the higher-priced, V6-powered sport sedan.
But with consumers increasingly placing importance on fuel economy and accepting hybrids as a normal type of vehicle, 2012 marks the first time the Camry Hybrid will be sold in more than one trim level: a mid-grade LE and an upscale XLE.
Both trims represent a significant savings over the outgoing model. At a base price of $25,900, the Hybrid LE is a full $1,150 less expensive than the base 2011 model, and at a base price of $27,400, even the Hybrid XLE represents a savings of about $800 over a comparably-equipped 2011 model.
Other Cars to Consider
The obvious alternative to the 2012 Toyota Camry Hybrid is Toyota's own Prius. Similarly equipped, both cars cost about the same but the Prius does have a techier vibe. Those looking to save money and can do with less interior space will want to consider the Honda Insight and it's sub $20,000 price tag. The real Camry Hybrid challenger is the new Kia Optima Hybrid. It's about the same price as the Camry Hybrid LE but has a more youthful look and a few more compelling features. The Ford Fusion Hybrid is also worth considering although the Camry feels like a larger car overall.
AutoTrader.com Recommends
The best value is clearly the LE version of the Toyota Camry Hybrid. Its cost along with reasonable comfort and convenience features make it the best choice for buyers who want a functional, reliable, and efficient sedan.